The Brand Name AKURIT-4 Has Generic Salt :: Rifampicin 

AKURIT-4  Is From Company Lupin Priced :: Rs. 22.58

AKURIT-4 have Rifampicin is comes under Sub class #N/A of  Main Class #N/A

Main Medicine Class:: #N/A  Sub Medicine Class :: #N/A 

Indications for Drugs ::

Tuberculosis, Leprosy, Brucellosis, Meningitis , Legionnaire’s disease; Staphylococcal infections

Drug Dose ::

Adult: PO Tuberculosis 10 mg/kg/day or 2-3 times/wk. Max: 600 mg/day. Leprosy 600 mg once mthly. Prophylaxis against meningococcal meningitis 600 mg twice daily for 2 days. Prophylaxis against meningitis due to Haemophilus influenzae 600 mg/day for 4 days. PO/IV Brucellosis; Legionnaire’s disease; Staphylococcal infections 600-1,200 mg/day in divided doses.

Contraindication ::

Hypersensitivity, jaundice, severe hepatic disease. IM/SC admin. Porphyria. Not to be used for treatment of meningococcal disease.

Drug Precautions ::

Impaired hepatic or renal function. Elderly, malnourished or very young patients. Alcoholic patients. Monitor blood counts and liver function regularly. Body fluids may colour orange-red. Discontinue use if thrombocytopenia or purpura occurs. Pregnancy and lactation. Care should be taken during IV admin to prevent extravasation.

Drug Side Effects ::

GI disturbances, pseudomembranous colitis (rare), abnormalities of liver function, fatalities in those with liver disorders, influenza-like symptoms, skin reactions, eosinophilia, transient leucopenia, thrombocytopenia, purpura, shock, drowsiness, headache, ataxia, visual disturbances, menstrual irregularities. Reddish coloured urine and tears. IV: Thrombophloebitis; extravasation following local irritation and inflammation. Potentially Fatal: Hepatitis or shock-like syndrome with hepatic involvement.

Pregnancy category ::

3

Drug Mode of Action ::  

Rifampicin suppresses initiation of chain formation for RNA synthesis in susceptible bacteria by binding to the beta subunit of DNA-dependent RNA polymerase, thus blocking RNA transcription.

Drug Interactions ::

May accelerate the metabolism and reduce the effect of drugs that are metabolised by CYP450 enzymes (e.g. quinidine, phenytoin, theophylline). Decreased concentrations of atovaquone and increased concentrations of rifampicin when taken concomitantly. Concurrent use of ketoconazole and rifampicin may result in decreased serum concentrations of both drugs. May decrease serum concentrations of enalaprilat. Reduced absorption by antacids. Increased risk of hepatotoxicity w/ halothane or isoniazid. Potentially Fatal: Increased potential for hepatotoxicity when taken concomitantly w/ saquinavir/ritonavir combination.